How to Prepare Pathology for FMGE 2026: High-Yield Topics and Strategy
By Dr. Utsav Bhattacherjee, MBBS, MBA · 26 August 2026 · 9 min read
Pathology bridges basic science and clinical medicine more directly than almost any other pre-clinical subject, which is exactly why it is tested heavily — a pathology finding is often the fastest route to a diagnosis in a clinical vignette. The subject rewards pattern recognition: a specific type of necrosis, a specific inflammatory cell type, a specific tumor marker, each pointing toward a defined answer.
FMGE Pathology high yield topics
- Types of necrosis — recognising the pattern and the clinical context each is associated with.
- Acute versus chronic inflammation — the cell types and time courses that distinguish them.
- Neoplasia — the features separating benign from malignant, and the grading and staging logic.
- Tumor markers — matching marker to malignancy, and understanding their clinical use.
- Hematopathology — classification of anemias and leukemias by mechanism.
- Genetic and chromosomal disorders — the classic syndromes and their defining features.
Types of necrosis: pattern recognition worth memorising
| Type | Classic context |
|---|---|
| Coagulative | Ischemic injury in most solid organs (e.g. myocardial infarction) — architecture is preserved for a time |
| Liquefactive | Brain infarction and bacterial abscesses — enzymatic digestion dissolves tissue into liquid |
| Caseous | Tuberculosis — a distinctive cheese-like combination of coagulative and liquefactive features |
| Fat necrosis | Acute pancreatitis — released lipases digest peripancreatic fat, often with visible calcium soap formation |
| Fibrinoid | Immune-mediated vascular damage, seen in conditions like malignant hypertension and vasculitis |
| Gangrenous | Ischemic limb or bowel — essentially coagulative necrosis with superimposed infection in the wet form |
Recognising which necrosis type a described clinical scenario points to is often the fastest route to the underlying diagnosis, especially for tuberculosis (caseous) and acute pancreatitis (fat necrosis), which are both frequently tested through this exact pattern.
Acute vs chronic inflammation
Acute inflammation is dominated by neutrophils and develops over minutes to days, characterised by vascular changes (vasodilation, increased permeability) and the classic cardinal signs — redness, heat, swelling, pain and loss of function. Chronic inflammation is dominated by macrophages, lymphocytes and plasma cells, developing over weeks to months, and is associated with tissue destruction alongside attempted repair (fibrosis, angiogenesis) occurring simultaneously. Granulomatous inflammation — a specific pattern of chronic inflammation featuring organised collections of activated macrophages — is worth knowing as its own category, since it is classically associated with tuberculosis, sarcoidosis and certain fungal infections, and its presence on a pathology description is often the key clue in a question.
Benign vs malignant: the features that actually distinguish them
| Feature | Benign | Malignant |
|---|---|---|
| Growth rate | Slow | Typically rapid |
| Borders | Well-circumscribed, often encapsulated | Irregular, invasive |
| Differentiation | Well-differentiated, resembles tissue of origin | Ranges from well to poorly differentiated |
| Mitotic activity | Low | Often high, with abnormal mitotic figures |
| Metastasis | Does not metastasise | Capable of metastasis |
Grading assesses how differentiated a tumor is (how closely it resembles normal tissue), while staging assesses how far it has spread anatomically — these are frequently confused, but they answer different clinical questions and are tested as a distinct pair of concepts rather than interchangeable terms.
Tumor markers worth memorising
- AFP — hepatocellular carcinoma and yolk sac tumors.
- CEA — colorectal cancer, though nonspecific (also raised in several other cancers and in smokers).
- CA-125 — ovarian cancer.
- PSA — prostate cancer.
- Beta-hCG — choriocarcinoma and germ cell tumors.
- CA 19-9 — pancreatic cancer.
The exam-relevant nuance worth remembering: most tumor markers are better suited to monitoring treatment response and detecting recurrence than to primary screening, since they generally lack the specificity needed for reliable population-level screening.
Hematopathology: organising anemia and leukemia
Anemia classification by red cell size (microcytic, normocytic, macrocytic) is a foundational framework that recurs across Pathology and Medicine alike — iron deficiency and thalassemia for microcytic, megaloblastic anemia for macrocytic, and hemolytic or acute blood loss for normocytic with an appropriately elevated reticulocyte response. Leukemia splits first into acute versus chronic (based on how rapidly it progresses and the maturity of the abnormal cells) and then into myeloid versus lymphoid lineage. Acute leukemias present with a rapid onset and immature blast cells; chronic leukemias tend to have a more indolent course with more mature-appearing abnormal cells, at least early in the disease course.
Genetic and chromosomal disorders: the classic syndromes
A defined set of chromosomal disorders repeats reliably across exams, each with a signature clinical picture worth memorising directly. Down syndrome (trisomy 21) presents with characteristic facial features, intellectual disability, and an increased risk of congenital heart defects and later leukemia. Turner syndrome (45,XO) presents in phenotypic females with short stature, webbed neck and primary amenorrhea from ovarian dysgenesis. Klinefelter syndrome (47,XXY) presents in phenotypic males with tall stature, gynecomastia and infertility from testicular dysgenesis. Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13) both carry a much more severe prognosis than Down syndrome, with multiple major organ malformations and significantly reduced survival — a severity gradient worth knowing, since it is a common way these three trisomies get compared in a single question.
Cellular adaptation: hypertrophy, hyperplasia, atrophy and metaplasia
Cells respond to changing physiological demands through a defined set of adaptations, and recognising which one a scenario describes is a recurring low-effort, high-value skill. Hypertrophy is an increase in cell size (classic example: cardiac muscle responding to chronic hypertension). Hyperplasia is an increase in cell number, occurring only in tissues capable of cell division. Atrophy is a decrease in cell size and function, often from disuse, reduced blood supply, or loss of hormonal stimulation. Metaplasia is the reversible replacement of one differentiated cell type with another better suited to a new stressor — the classic example being the replacement of normal esophageal squamous epithelium with columnar epithelium in Barrett’s esophagus, in response to chronic acid reflux. Metaplasia is worth flagging specifically because it can be a precursor to dysplasia and, eventually, malignancy if the underlying stressor is not addressed — a progression that shows up often in questions linking chronic irritation to cancer risk.
Apoptosis vs necrosis: a distinction worth keeping separate
Necrosis and apoptosis are both forms of cell death, but they are mechanistically and clinically distinct in ways the exam tests directly. Necrosis is typically pathological, triggered by an external insult like ischemia or toxins, and provokes an inflammatory response as cell contents spill into surrounding tissue. Apoptosis is a programmed, energy-dependent process — often physiological (normal tissue turnover, embryological development) but also pathological in some contexts (a virally infected cell being eliminated) — and characteristically does not provoke inflammation, since the cell fragments into membrane-bound bodies that are cleared without spilling their contents. A question describing an inflammatory response accompanying cell death is pointing toward necrosis; one describing an isolated cell dying without surrounding tissue reaction is pointing toward apoptosis. This distinction also underlies why apoptosis is exploited therapeutically — many chemotherapy agents work by pushing cancer cells toward apoptosis rather than causing outright necrosis, which is part of why understanding the mechanism matters beyond pure exam recall.
A smart study plan for FMGE Pathology
- Build a necrosis-to-context reference table early — it is a small, defined list that pays off repeatedly across different clinical scenarios.
- Treat tumor markers as a fixed, learnable list rather than an open-ended category, since the same handful repeat across questions.
- Practise distinguishing benign from malignant using the feature table above, since vignette questions often describe findings rather than stating the diagnosis outright.
- Connect Pathology concepts back to their clinical subjects (necrosis types to Medicine and Surgery presentations, tumor markers to oncology questions) rather than studying them in isolation — that is how they are actually tested.
For the complete high-yield picture across every FMGE subject, see our FMGE high yield topics guide, and for how Pathology fits into your overall timeline, our FMGE December 2026 preparation strategy covers the sequencing across subjects.
